Anbio has introduced a comprehensive RT-PCR solution that encompasses both pharmacogenomic and non-pharmacogenomic applications. The Anbio molecular diagnostic test menu spans multiple clinical applications including healthcare-associated infections, critical infectious disease, sexual health, virology, pharmacogenomics, and oncology.
Anbio molecular diagnostic tests can be employed in institutions of any size, from small medical clinics to high-volume reference laboratories and hospitals, to access the speed and accuracy of molecular diagnostics.
The firm’s approach to molecular diagnostics (MDx) simplifies the challenges associated with RT-PCR, catering to the requirements of both novice and experienced users in quantitative reverse transcriptase PCR (qRT-PCR). Reagent kits are designed to be compatible with a wide range of RT-PCR readers, allowing for seamless integration into existing workflows. Moreover, the kits can be customised and optimised to meet the specific needs of even the most demanding assays.
Anbio’s portfolio of pharmacogenomic assays supports healthcare providers in analysing genetic variations that impact drug metabolism, efficacy, and toxicity, enabling the determination of personalised treatment options. With a robust selection of RT-PCR tests tailored for pharmacogenomics, Anbio is committed to providing comprehensive solutions in this field.
"The Anbio molecular RT-PCR solution sets its sights on delivering a cost-effective and all-encompassing answer to healthcare providers," said Jack Davis, Chief Business Officer at Anbio. "Our RT-PCR solution ensures rapid, precise, and dependable results for a wide range of analytes at the point of care, guaranteeing swifter diagnosis and heightened accuracy."